Xtant Medical Receives Clearance of Expanded Indication for Ilium Fixation and Deformity

Medical Receives Clearance of Expanded Indication for Ilium Fixation and Deformity

Mont., Dec. 01, 2015 -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products

and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, Inc. received FDA clearance of expanded

indications to include ilium fixation as well as extended length screws for the Fortex and the Xpress 2 Pedicle Screw

extended length screws are compatible with X-spine's current Fortex and Xpress instrument systems, offering a comprehensive

pedicle screw portfolio. These dual lead, non-cannulated screws are indicated for use in posterior, non-cervical, T1-S2/Ilium

pedicle spinal fixation. They are intended to provide immobilization and stabilization of spinal segments in skeletally mature

patients as an adjunct to fusion in the treatment of degenerative spondylolisthesis, fracture, dislocation, scoliosis, kyphosis,

spinal tumors, and failed previous fusion.

biomechanical forces make long segment lumbosacral spine fixation challenging to perform," states Dr. David Kirschman, Chief

Scientific Officer of Xtant Medical and President of X-spine Systems. "Expanded indications into the ilium with extended

implants will enhance fixation and enable surgeons to treat a wider variety of pathologies than sacral fixation alone."

Xtant Medical Holdings

Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic

and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics

for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment

of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies

in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological

and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

Cautions Regarding Forward-looking Statements

press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements

that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue,"

"efforts," "expects," "anticipates," "intends," "plans," "believes,"

"estimates," "projects," "forecasts," "strategy," "will," "goal,"

"target," "prospects," "potential," "optimistic," "confident," "likely,"

"probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking

statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially

depending on a variety of important factors, including, among others: the Company's ability to successfully integrate the acquisition

of X-spine; the ability of the Company's sales force to achieve expected results; the Company's ability to meet its existing and

anticipated contractual obligations, including financial covenant and other obligations contained in the Company's secured lending

facility; the Company's ability to manage cash flow; the Company's ability to develop, market, sell and distribute desirable applications,

products and services and to protect its intellectual property; the ability of the Company's customers to pay and the timeliness

of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the

Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes

in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other

factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under

the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking

statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except